B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $29 to $30.
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $29 to $30.